Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 5/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PTAFR | P25105 | 3/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21045108 | 1.00 | FYN (0.40) | FYNCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL29411428 | 0.87 | LMNA (0.43) | CYP3A4LMNAHIF1A | |
| SCHEMBL21045521 | 0.87 | LMNA (0.43) | CYP3A4LMNAHIF1A | |
| SCHEMBL21045432 | 0.84 | KDM4E (0.49) | FYNROCK2ROCK1PTAFRHIF1A | |
| SCHEMBL29411462 | 0.84 | KDM4E (0.49) | FYNROCK2ROCK1PTAFRHIF1A | |
| SCHEMBL21045093 | 0.81 | HDAC3 (0.43) | FYNCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL29411374 | 0.81 | HDAC3 (0.43) | FYNCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL21045146 | 0.79 | PTAFR (0.46) | FYNROCK2ROCK1PTAFRHIF1A | |
| SCHEMBL29411571 | 0.79 | PTAFR (0.46) | FYNROCK2ROCK1PTAFRHIF1A | |
| SCHEMBL21045275 | 0.77 | PTAFR (0.48) | FYNROCK2ROCK1PTAFREGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188035-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE LLC (US) | 2025-06-12 | — | — | US | disclosed |
| US-12247010-B2 | Tubulin inhibitors | LIN BIOSCIENCE INC. (TW) | 2025-03-11 | — | — | US | disclosed |
| US-20220089539-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE INC. (TW) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089539-A1 | TUBULIN INHIBITORS | TUBB3, TUBB1, TUBB | FYN 2141/4885CYP1A2 3826/4885CYP3A4 3925/4885 |
| US-12247010-B2 | Tubulin inhibitors | TUBB3, TUBB1, TUBB | FYN 2141/4885CYP1A2 3826/4885CYP3A4 3925/4885 |
| US-20250188035-A1 | TUBULIN INHIBITORS | TUBB3, TUBB1, TUBB | FYN 2141/4885CYP1A2 3826/4885CYP3A4 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.